BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experiencing stro

Donation to fund additional testing centers, medical staff support and blood drives in underserved and disadvantaged communities

BioInvent International AB (“BioInvent”) (OMXS: BINV) today announces, on behalf of the nomination committee and major shareholders, the proposal to elect Dr. Thomas Hecht as new Board member at the Extraordinary General Meeting on July 3, 2020 , in accordance with the convening notice to the Extraordinary General Meeting.

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplement

AppBus, an accelerator of business transformation, and Mednet, a provider of eClinical solutions for the global life sciences community, announced they have partnered together to address the rapidly evolving demands and requirements of clinical trials.

As previously disclosed, the US authority FDA has approved SpectraCure’s new and revised study protocol for the clinical study on patients with recurrent prostate cancer.

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralization by CatalYm’s CTL-002 antibody in cancer have been selected for presentation during the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 – 24, 2020. “ Tumor-derived G

While initial hot spots of COVID-19 were centered in dense urban areas, infections have rapidly expanded into suburban and rural settings – in areas with a population between 2,500 and 50,000 according to The Henry J. Kaiser Family Foundation.

Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Michael T. Lotze as chief cellular therapy officer (CCO) and Dr. Robert J. Brown as vice president of clinical development.

OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO